Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04086745 · ClinicalTrials.gov registry record · Phase 4

A Study of Baricitinib in Participants With Rheumatoid Arthritis

A Phase 4 study of Rheumatoid Arthritis, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 4
Development phase
1,317
Enrollment target
20
Study locations

NCT04086745 is a Phase 4 study of Rheumatoid Arthritis that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,317 participants, below the 4,684-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04086745, a Phase 4 study of Rheumatoid Arthritis, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 4
Development phase
1,317 participants
Enrollment target
20
Study locations

Study Summary

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG Baricitinib
  • DRUG TNF Inhibitor

Study Locations (20)

California

  • Providence St. Joseph's Medical Center - Burbank
  • Hope Clinical Research, Inc. - Canoga Park
  • Medvin Clinical Research - Covina - Covina
  • TriWest Research Associates LLC - El Cajon
  • Newport Huntington Med Grp - Huntington Beach
  • BioSolutions Clinical Research Center - La Mesa
  • Valerius Medical Group and Research Center of Greater Long Beach - Los Alamitos
  • R. Srinivasan, M.D., Inc. dba Monterey Park Medical Center - Monterey Park
  • ACRC Studies - Poway
  • Desert Medical Advances - Rancho Mirage
  • Purushotham & Akther Kotha MD Inc - San Diego
  • East Bay Rheumatology Medical Group, Inc - San Leandro
  • Providence Medical Foundation - Santa Rosa
  • Dan La, MD Inc - Tujunga

Arizona

  • Arizona Research Clinic PLLC - Chandler
  • Arizona Arthritis & Rheumatology Associates, P. C. - Mesa
  • Arizona Arthritis & Rheumatology Research - Paradise Valley
  • Sun Valley Arthritis Center, LTD - Peoria
  • Arizona Arthritis & Rheumatology Associates - Phoenix

Arkansas

  • Arthritis and Rheumatism Associates - Jonesboro

Trial Details

FieldValue
Enrollment Target 1,317 participants
Start Date 2020-02-14
Est. Completion 2025-05-19
Phase Phase 4

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04086745

The ClinicalTrials.gov registry entry for NCT04086745 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,317 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,684-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (72% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Baricitinib is the first listed.

NCT04086745 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Arkansas.

Frequently Asked Questions

What is clinical trial NCT04086745 about?

NCT04086745 is a clinical study titled "A Study of Baricitinib in Participants With Rheumatoid Arthritis". This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).

What is the current status of trial NCT04086745?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,317 participants. The study started on 2020-02-14. Estimated completion is 2025-05-19.

What conditions does trial NCT04086745 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT04086745?

The interventions under investigation include: Baricitinib (DRUG), TNF Inhibitor (DRUG).

Who is sponsoring clinical trial NCT04086745?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04086745 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.